Bile Duct Cancer
92
21
27
30
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
11 trials with published results (12%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.6%
7 terminated out of 92 trials
81.1%
-5.4% vs benchmark
8%
7 trials in Phase 3/4
37%
11 of 30 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 30 completed trials
Clinical Trials (92)
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Integrated Cancer Repository for Cancer Research
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
The Comparison of Miniinvasive and Open Pancreaticoduodenectomy for Cancer Pancreaticobiliary Zone
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder
Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents
Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors